The efficacy of N-acetyl cysteine as an adjunctive treatment for first episode psychosis

N-乙酰半胱氨酸辅助治疗首发精神病的疗效

• 批准号: nhmrc : GNT1125778
• 负责人: A/Pr Seetal Dodd
• 金额: $ 214.31万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/efficacy-n-acetyl-episode-psychosis/1347508
• 关键词: efficacy; acetyl; cysteine; adjunctive; treatment

First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.

首次发作的精神病可能预示着毁灭性的慢性疾病。精神病遵循一个分阶段的、渐进的路径。有证据表明，如果在疾病早期阶段给予适当的治疗，可以减少甚至避免疾病的进展。该项目将测试对经历过首次精神病发作的年轻人施用 N-乙酰半胱氨酸 (NAC) 是否有助于防止这种早期精神病经历发展为慢性疾病。